Skip to main content

The use of histotripsy as intratumoral immunotherapy beyond tissue ablation-the rationale for exploring the immune effects of histotripsy.

Publication ,  Journal Article
Osada, T; Jiang, X; Zhao, Y; Chen, M; Kreager, BC; Wu, H; Kim, H; Ren, J; Snyder, J; Zhong, P; Morse, MA; Lyerly, HK
Published in: Int J Hyperthermia
2023

Mechanical high-intensity focused ultrasound (M-HIFU), which includes histotripsy, is a non-ionizing, non-thermal ablation technology that can be delivered by noninvasive methods. Because acoustic cavitation is the primary mechanism of tissue disruption, histotripsy is distinct from the conventional HIFU techniques resulting in hyperthermia and thermal injury. Phase I human trials have shown the initial safety and efficacy of histotripsy in treating patients with malignant liver tumors. In addition to tissue ablation, a promising benefit of M-HIFU has been stimulating a local and systemic antitumor immune response in preclinical models and potentially in the Phase I trial. Preclinical studies combining systemic immune therapies appear promising, but clinical studies of combinations have been complicated by systemic toxicities. Consequently, combining M-HIFU with systemic immunotherapy has been demonstrated in preclinical models and may be testing in future clinical studies. An additional alternative is to combine intratumoral M-HIFU and immunotherapy using microcatheter-placed devices to deliver both M-HIFU and immunotherapy intratumorally. The promise of M-HIFU as a component of anti-cancer therapy is promising, but as forms of HIFU are tested in preclinical and clinical studies, investigators should report not only the parameters of the energy delivered but also details of the preclinical models to enable analysis of the immune responses. Ultimately, as clinical trials continue, clinical responses and immune analysis of patients undergoing M-HIFU including forms of histotripsy will provide opportunities to optimize clinical responses and to optimize application and scheduling of M-HIFU in the context of the multi-modality care of the cancer patient.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Int J Hyperthermia

DOI

EISSN

1464-5157

Publication Date

2023

Volume

40

Issue

1

Start / End Page

2263672

Location

England

Related Subject Headings

  • Oncology & Carcinogenesis
  • Liver Neoplasms
  • Immunotherapy
  • Humans
  • High-Intensity Focused Ultrasound Ablation
  • Carcinoma, Hepatocellular
  • 3202 Clinical sciences
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Osada, T., Jiang, X., Zhao, Y., Chen, M., Kreager, B. C., Wu, H., … Lyerly, H. K. (2023). The use of histotripsy as intratumoral immunotherapy beyond tissue ablation-the rationale for exploring the immune effects of histotripsy. Int J Hyperthermia, 40(1), 2263672. https://doi.org/10.1080/02656736.2023.2263672
Osada, Takuya, Xiaoning Jiang, Yuhang Zhao, Mengyue Chen, Benjamin C. Kreager, Huaiyu Wu, Howuk Kim, et al. “The use of histotripsy as intratumoral immunotherapy beyond tissue ablation-the rationale for exploring the immune effects of histotripsy.Int J Hyperthermia 40, no. 1 (2023): 2263672. https://doi.org/10.1080/02656736.2023.2263672.
Osada T, Jiang X, Zhao Y, Chen M, Kreager BC, Wu H, et al. The use of histotripsy as intratumoral immunotherapy beyond tissue ablation-the rationale for exploring the immune effects of histotripsy. Int J Hyperthermia. 2023;40(1):2263672.
Osada, Takuya, et al. “The use of histotripsy as intratumoral immunotherapy beyond tissue ablation-the rationale for exploring the immune effects of histotripsy.Int J Hyperthermia, vol. 40, no. 1, 2023, p. 2263672. Pubmed, doi:10.1080/02656736.2023.2263672.
Osada T, Jiang X, Zhao Y, Chen M, Kreager BC, Wu H, Kim H, Ren J, Snyder J, Zhong P, Morse MA, Lyerly HK. The use of histotripsy as intratumoral immunotherapy beyond tissue ablation-the rationale for exploring the immune effects of histotripsy. Int J Hyperthermia. 2023;40(1):2263672.

Published In

Int J Hyperthermia

DOI

EISSN

1464-5157

Publication Date

2023

Volume

40

Issue

1

Start / End Page

2263672

Location

England

Related Subject Headings

  • Oncology & Carcinogenesis
  • Liver Neoplasms
  • Immunotherapy
  • Humans
  • High-Intensity Focused Ultrasound Ablation
  • Carcinoma, Hepatocellular
  • 3202 Clinical sciences
  • 1103 Clinical Sciences